Chinese Journal of Tissue Engineering Research ›› 2013, Vol. 17 ›› Issue (11): 1917-1924.doi: 10.3969/j.issn.2095-4344.2013.11.003

Previous Articles     Next Articles

Effect of ginsenoside Rg1 on type Ⅱ collagen expression in chondrocytes

Zhang Ye-yong, Cheng Wen-dan, Chen Zhe-feng, Fan Wei-min, Liu Feng   

  1. Department of Orthopedics, First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, Jiangsu Province, China
  • Received:2012-12-08 Revised:2012-12-29 Online:2013-03-12 Published:2013-03-12
  • Contact: Liu Feng, Doctor, Associate professor, Master’s supervisor, Department of Orthopedics, First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, Jiangsu Province, China njliuf@hotmail.com
  • About author:Zhang Ye-yong★, Master, Department of Orthopedics, First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, Jiangsu Province, China 402321300@qq.com

Abstract:

BACKGROUND: Ginseng has a wide range of pharmacological activities, such as anti-inflammatory, anti-stress, and immunomodulatory roles. Its major pharmacological active ingredient is the ginsenoside, and Rg1 is an active ingredient with a higher content.
OBJECTIVE: To investigate the effect of ginsenoside Rg1 on type Ⅱ collagen and cyclooxygenase-2 mRNA expression in chondrocytes of an interleukin-1β-induced osteoarthritis model.
METHODS: Undamaged cartilage from osteoarthritis patients undergoing total knee arthroplasty was harvested and cultured. The effect of ginsenoside Rg1 (0.001, 0.01, 0.1, 1, 10, 100 mg/L) on proliferation rate of passage 2 chondrocytes was analyzed by Cell Counting Kit-8. Then the passage 2 chondrocytes were divided into blank group, control group and experimental group randomly. Dulbecco’s modified Eagle’s medium was added into the blank group alone. Interleukin-1β at a dose of 10 μg/L was added into the control group to establish an osteoarthritis model. While 10 μg/L interleukin-1β and ginsenoside Rg1 with different concentrations (0.1, 1, 10, 100 mg/L) were added into the experimental group concomitantly. After 24-hour in vitro culture, the expressions of type Ⅱ collagen and cyclooxygenase-2 gene in human articular chondrocytes were analyzed by reverse transcription-PCR.
RESULTS AND CONCLUSION: Promotive effect of the certain concentration of ginsenoside Rg1 on chondrocyte proliferation was observed by the result of cell counting kit-8 analysis. However, compared with the blank control group, the lower concentration of ginsenoside Rg1 (0.001, 0.01, 0.1, 1 mg/L) could not stimulate the proliferation rate of chondrocytes significantly (P > 0.05); only the higher concentration of ginsenoside Rg1 (10 and 100 mg/L) could stimulate the proliferation rate of chondrocytes significantly (P < 0.05). From the results of cell counting kit-8 analysis, compared with the blank group, the type Ⅱ collagen mRNA expression significantly decreased and cyclooxygenase-2 mRNA expression significantly increased in chondrocytes of the control group (P < 0.05). When 10 μg/L interleukin-1β and ginsenoside Rg1 of different concentrations (0.1 and 1 mg/L) were added concomitantly in the experimental group, the type Ⅱ collagen and cyclooxygenase-2 mRNA expression had no obvious changes compared with the control group (P > 0.05). Meanwhile, when 10 μg/L interleukin-1β and ginsenoside Rg1 of different concentrations (10, 100 mg/L) were added concomitantly in the experimental group, the type Ⅱ collagen mRNA expression significantly increased and cyclooxygenase-2 mRNA expression significantly decreased compared with the control group (P < 0.05). These findings showed that interleukin-1β induced decreased mRNA expression of type Ⅱ collagen and increased mRNA expression of cyclooxygenase-2 could be antagonized by somewhat concentration of ginsenoside Rg1.

Key words: tissue construction, cartilage tissue construction, ginsenoside Rg1, type Ⅱ collagen, cyclooxygenase-2, chondrocytes, interleukin-1 beta, reverse transcription-PCR, osteoarthritis, Cell Counting Kit-8, tissue construction photographs-containing paper

CLC Number: